Biogen Idec Canada announced today that Tecfidera (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. Tecfidera is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). Tecfidera is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.

Effective June 24, 2014, Tecfidera is eligible for reimbursement as a first-line monotherapy for people diagnosed with RRMS according to the current McDonald clinical criteria(2) and magnetic resonance imaging (MRI) evidence, when prescribed by a neurologist from a designated MS clinic, who meet the following criteria: is 18 years of age or older; meet the Limited Coverage criteria; has had at least two disabling attacks of MS in the previous two years; and is ambulatory with or without aid with an Expanded Disability Status Scale (EDSS) score of 6.5 or less.

For more details, go to: http://www.marketwatch.com/story/british-columbia-to-reimburse-tecfideratm-a-first-line-oral-treatment-for-multiple-sclerosis-2014-06-25